Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma
Background Addition of anti‐GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement‐mediated. Hu14.18K322A is a humanized anti‐GD2 antibody designed to diminish complement activation and...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2015-02, Vol.62 (2), p.224-228 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 228 |
|---|---|
| container_issue | 2 |
| container_start_page | 224 |
| container_title | Pediatric blood & cancer |
| container_volume | 62 |
| creator | Anghelescu, Doralina L. Goldberg, Jacob L. Faughnan, Lane G. Wu, Jianrong Mao, Shenghua Furman, Wayne L. Santana, Victor M. Navid, Fariba |
| description | Background
Addition of anti‐GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement‐mediated. Hu14.18K322A is a humanized anti‐GD2 antibody designed to diminish complement activation and induce less pain. We compare the pain outcomes in patients treated with ch14.18 and those treated with hu14.18K322A, and explore dose‐dependent relationships between pain scores, opioid requirements, and complement levels in patients treated with hu14.18K322A.
Procedure
Opioid (morphine equivalent mg/kg) and anxiolytic requirements during course 1 (4 days) in patients treated with hu14.18K322A and ch14.18 were reviewed. Correlations between antibody dose and pain scores, opioid requirements, and complement levels were examined for patients receiving hu14.18K322A.
Results
Patients treated with hu14.18K322A (n = 19) had lower opioid requirements than those who received ch14.18 (n = 9). The differences in median opioid requirements (mg/kg) were statistically significant for the overall course (1.57 vs. 2.41, P = 0.019) as well as for Days 3 (0.34 vs. 0.65, P = 0.005), and 4 (0.32 vs. 0.64, P = 0.010). No difference in anxiolytic use was observed between the two groups. In the group treated with hu14.18K322A, we found a positive correlation between antibody dose administered and pain scores, but no correlation between antibody dose and opioid requirements or changes in complement levels.
Conclusions
In this retrospective analysis, hu14.18K322A induced less pain than ch14.18 based on opioid requirements. Pediatr Blood Cancer 2015;62:224–228. © 2014 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/pbc.25280 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4425626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1891867504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5140-754416f83029122eca74492bc624610faeb6281bbf32eb208cd793c13f3062a83</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhiMEoh9w4A-gSFzoIa09_swFqSywgErhAKrUi2V7HeqSxMF2WPrvcbvtCpCQOM1I88yrd-atqicYHWKE4Ggy9hAYSHSv2sWMsoYhLO5ve9TuVHspXRaUIyYfVjvAiARBYbc6X4Rh0tGnMNahqyftS52zDYNLtXF57dxY53Wo9Zh9s3wFN40JK1_mhZ109m7MqV77fFGPbo7B9DrlMOhH1YNO98k9vq371Zc3rz8v3jYnH5fvFscnjWWYokYwSjHvJEHQYgBntaC0BWM5UI5Rp53hILExHQFnAEm7Ei2xmHQEcdCS7FcvNrrTbAa3ssVO1L2aoh90vFJBe_XnZPQX6mv4oSgFxoEXgee3AjF8n13KavDJur7XowtzUli2WHLBEP0PFDjHwFtU0Gd_oZdhjmP5RKEkEi0wem3-YEPZGFKKrtv6xkhdh6tKuOom3MI-_f3QLXmXZgGONsDa9-7q30rq08vFnWSz2fApu5_bDR2_KS6IYOrsdKnaMwbvTz-cK0J-AfgsvIw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1880792548</pqid></control><display><type>article</type><title>Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Anghelescu, Doralina L. ; Goldberg, Jacob L. ; Faughnan, Lane G. ; Wu, Jianrong ; Mao, Shenghua ; Furman, Wayne L. ; Santana, Victor M. ; Navid, Fariba</creator><creatorcontrib>Anghelescu, Doralina L. ; Goldberg, Jacob L. ; Faughnan, Lane G. ; Wu, Jianrong ; Mao, Shenghua ; Furman, Wayne L. ; Santana, Victor M. ; Navid, Fariba</creatorcontrib><description>Background
Addition of anti‐GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement‐mediated. Hu14.18K322A is a humanized anti‐GD2 antibody designed to diminish complement activation and induce less pain. We compare the pain outcomes in patients treated with ch14.18 and those treated with hu14.18K322A, and explore dose‐dependent relationships between pain scores, opioid requirements, and complement levels in patients treated with hu14.18K322A.
Procedure
Opioid (morphine equivalent mg/kg) and anxiolytic requirements during course 1 (4 days) in patients treated with hu14.18K322A and ch14.18 were reviewed. Correlations between antibody dose and pain scores, opioid requirements, and complement levels were examined for patients receiving hu14.18K322A.
Results
Patients treated with hu14.18K322A (n = 19) had lower opioid requirements than those who received ch14.18 (n = 9). The differences in median opioid requirements (mg/kg) were statistically significant for the overall course (1.57 vs. 2.41, P = 0.019) as well as for Days 3 (0.34 vs. 0.65, P = 0.005), and 4 (0.32 vs. 0.64, P = 0.010). No difference in anxiolytic use was observed between the two groups. In the group treated with hu14.18K322A, we found a positive correlation between antibody dose administered and pain scores, but no correlation between antibody dose and opioid requirements or changes in complement levels.
Conclusions
In this retrospective analysis, hu14.18K322A induced less pain than ch14.18 based on opioid requirements. Pediatr Blood Cancer 2015;62:224–228. © 2014 Wiley Periodicals, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.25280</identifier><identifier>PMID: 25382742</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adolescent ; anti-GD2 antibodies ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Child ; Child, Preschool ; Complement Activation - immunology ; Complement Inactivator Proteins - therapeutic use ; Complement System Proteins - drug effects ; Female ; Gangliosides - antagonists & inhibitors ; Gangliosides - immunology ; Hematology ; Humans ; Immunotherapy - methods ; Infant ; Male ; Neuralgia - drug therapy ; neuroblastoma ; Neuroblastoma - therapy ; Oncology ; opioids ; pain ; pediatric oncology ; Pediatrics ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Pediatric blood & cancer, 2015-02, Vol.62 (2), p.224-228</ispartof><rights>2014 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5140-754416f83029122eca74492bc624610faeb6281bbf32eb208cd793c13f3062a83</citedby><cites>FETCH-LOGICAL-c5140-754416f83029122eca74492bc624610faeb6281bbf32eb208cd793c13f3062a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.25280$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.25280$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25382742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anghelescu, Doralina L.</creatorcontrib><creatorcontrib>Goldberg, Jacob L.</creatorcontrib><creatorcontrib>Faughnan, Lane G.</creatorcontrib><creatorcontrib>Wu, Jianrong</creatorcontrib><creatorcontrib>Mao, Shenghua</creatorcontrib><creatorcontrib>Furman, Wayne L.</creatorcontrib><creatorcontrib>Santana, Victor M.</creatorcontrib><creatorcontrib>Navid, Fariba</creatorcontrib><title>Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>Background
Addition of anti‐GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement‐mediated. Hu14.18K322A is a humanized anti‐GD2 antibody designed to diminish complement activation and induce less pain. We compare the pain outcomes in patients treated with ch14.18 and those treated with hu14.18K322A, and explore dose‐dependent relationships between pain scores, opioid requirements, and complement levels in patients treated with hu14.18K322A.
Procedure
Opioid (morphine equivalent mg/kg) and anxiolytic requirements during course 1 (4 days) in patients treated with hu14.18K322A and ch14.18 were reviewed. Correlations between antibody dose and pain scores, opioid requirements, and complement levels were examined for patients receiving hu14.18K322A.
Results
Patients treated with hu14.18K322A (n = 19) had lower opioid requirements than those who received ch14.18 (n = 9). The differences in median opioid requirements (mg/kg) were statistically significant for the overall course (1.57 vs. 2.41, P = 0.019) as well as for Days 3 (0.34 vs. 0.65, P = 0.005), and 4 (0.32 vs. 0.64, P = 0.010). No difference in anxiolytic use was observed between the two groups. In the group treated with hu14.18K322A, we found a positive correlation between antibody dose administered and pain scores, but no correlation between antibody dose and opioid requirements or changes in complement levels.
Conclusions
In this retrospective analysis, hu14.18K322A induced less pain than ch14.18 based on opioid requirements. Pediatr Blood Cancer 2015;62:224–228. © 2014 Wiley Periodicals, Inc.</description><subject>Adolescent</subject><subject>anti-GD2 antibodies</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Complement Activation - immunology</subject><subject>Complement Inactivator Proteins - therapeutic use</subject><subject>Complement System Proteins - drug effects</subject><subject>Female</subject><subject>Gangliosides - antagonists & inhibitors</subject><subject>Gangliosides - immunology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Infant</subject><subject>Male</subject><subject>Neuralgia - drug therapy</subject><subject>neuroblastoma</subject><subject>Neuroblastoma - therapy</subject><subject>Oncology</subject><subject>opioids</subject><subject>pain</subject><subject>pediatric oncology</subject><subject>Pediatrics</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhiMEoh9w4A-gSFzoIa09_swFqSywgErhAKrUi2V7HeqSxMF2WPrvcbvtCpCQOM1I88yrd-atqicYHWKE4Ggy9hAYSHSv2sWMsoYhLO5ve9TuVHspXRaUIyYfVjvAiARBYbc6X4Rh0tGnMNahqyftS52zDYNLtXF57dxY53Wo9Zh9s3wFN40JK1_mhZ109m7MqV77fFGPbo7B9DrlMOhH1YNO98k9vq371Zc3rz8v3jYnH5fvFscnjWWYokYwSjHvJEHQYgBntaC0BWM5UI5Rp53hILExHQFnAEm7Ei2xmHQEcdCS7FcvNrrTbAa3ssVO1L2aoh90vFJBe_XnZPQX6mv4oSgFxoEXgee3AjF8n13KavDJur7XowtzUli2WHLBEP0PFDjHwFtU0Gd_oZdhjmP5RKEkEi0wem3-YEPZGFKKrtv6xkhdh6tKuOom3MI-_f3QLXmXZgGONsDa9-7q30rq08vFnWSz2fApu5_bDR2_KS6IYOrsdKnaMwbvTz-cK0J-AfgsvIw</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Anghelescu, Doralina L.</creator><creator>Goldberg, Jacob L.</creator><creator>Faughnan, Lane G.</creator><creator>Wu, Jianrong</creator><creator>Mao, Shenghua</creator><creator>Furman, Wayne L.</creator><creator>Santana, Victor M.</creator><creator>Navid, Fariba</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201502</creationdate><title>Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma</title><author>Anghelescu, Doralina L. ; Goldberg, Jacob L. ; Faughnan, Lane G. ; Wu, Jianrong ; Mao, Shenghua ; Furman, Wayne L. ; Santana, Victor M. ; Navid, Fariba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5140-754416f83029122eca74492bc624610faeb6281bbf32eb208cd793c13f3062a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>anti-GD2 antibodies</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Complement Activation - immunology</topic><topic>Complement Inactivator Proteins - therapeutic use</topic><topic>Complement System Proteins - drug effects</topic><topic>Female</topic><topic>Gangliosides - antagonists & inhibitors</topic><topic>Gangliosides - immunology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Infant</topic><topic>Male</topic><topic>Neuralgia - drug therapy</topic><topic>neuroblastoma</topic><topic>Neuroblastoma - therapy</topic><topic>Oncology</topic><topic>opioids</topic><topic>pain</topic><topic>pediatric oncology</topic><topic>Pediatrics</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anghelescu, Doralina L.</creatorcontrib><creatorcontrib>Goldberg, Jacob L.</creatorcontrib><creatorcontrib>Faughnan, Lane G.</creatorcontrib><creatorcontrib>Wu, Jianrong</creatorcontrib><creatorcontrib>Mao, Shenghua</creatorcontrib><creatorcontrib>Furman, Wayne L.</creatorcontrib><creatorcontrib>Santana, Victor M.</creatorcontrib><creatorcontrib>Navid, Fariba</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anghelescu, Doralina L.</au><au>Goldberg, Jacob L.</au><au>Faughnan, Lane G.</au><au>Wu, Jianrong</au><au>Mao, Shenghua</au><au>Furman, Wayne L.</au><au>Santana, Victor M.</au><au>Navid, Fariba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2015-02</date><risdate>2015</risdate><volume>62</volume><issue>2</issue><spage>224</spage><epage>228</epage><pages>224-228</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>Background
Addition of anti‐GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement‐mediated. Hu14.18K322A is a humanized anti‐GD2 antibody designed to diminish complement activation and induce less pain. We compare the pain outcomes in patients treated with ch14.18 and those treated with hu14.18K322A, and explore dose‐dependent relationships between pain scores, opioid requirements, and complement levels in patients treated with hu14.18K322A.
Procedure
Opioid (morphine equivalent mg/kg) and anxiolytic requirements during course 1 (4 days) in patients treated with hu14.18K322A and ch14.18 were reviewed. Correlations between antibody dose and pain scores, opioid requirements, and complement levels were examined for patients receiving hu14.18K322A.
Results
Patients treated with hu14.18K322A (n = 19) had lower opioid requirements than those who received ch14.18 (n = 9). The differences in median opioid requirements (mg/kg) were statistically significant for the overall course (1.57 vs. 2.41, P = 0.019) as well as for Days 3 (0.34 vs. 0.65, P = 0.005), and 4 (0.32 vs. 0.64, P = 0.010). No difference in anxiolytic use was observed between the two groups. In the group treated with hu14.18K322A, we found a positive correlation between antibody dose administered and pain scores, but no correlation between antibody dose and opioid requirements or changes in complement levels.
Conclusions
In this retrospective analysis, hu14.18K322A induced less pain than ch14.18 based on opioid requirements. Pediatr Blood Cancer 2015;62:224–228. © 2014 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25382742</pmid><doi>10.1002/pbc.25280</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2015-02, Vol.62 (2), p.224-228 |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4425626 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent anti-GD2 antibodies Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Child Child, Preschool Complement Activation - immunology Complement Inactivator Proteins - therapeutic use Complement System Proteins - drug effects Female Gangliosides - antagonists & inhibitors Gangliosides - immunology Hematology Humans Immunotherapy - methods Infant Male Neuralgia - drug therapy neuroblastoma Neuroblastoma - therapy Oncology opioids pain pediatric oncology Pediatrics Retrospective Studies Treatment Outcome |
| title | Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A54%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20pain%20outcomes%20between%20two%20anti-GD2%20antibodies%20in%20patients%20with%20neuroblastoma&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Anghelescu,%20Doralina%20L.&rft.date=2015-02&rft.volume=62&rft.issue=2&rft.spage=224&rft.epage=228&rft.pages=224-228&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.25280&rft_dat=%3Cproquest_pubme%3E1891867504%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1880792548&rft_id=info:pmid/25382742&rfr_iscdi=true |